Recent News

• 02.12.2026 - Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
• 02.04.2026 - Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
• 01.07.2026 - Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
• 12.11.2025 - Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Recent Filings

• 02.12.2026 - 8-K Current report
• 02.12.2026 - EX-99.1 EX-99.1
• 02.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.11.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.07.2026 - 8-K Current report
• 01.07.2026 - EX-99.1 EX-99.1
• 12.19.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.18.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors